APO-NEVIRAPINE TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

NEVIRAPINE

থেকে পাওয়া:

APOTEX INC

এটিসি কোড:

J05AG01

INN (আন্তর্জাতিক নাম):

NEVIRAPINE

ডোজ:

200MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

NEVIRAPINE 200MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0134602001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2012-11-07

পণ্য বৈশিষ্ট্য

_APO-NEVIRAPINE and APO-NEVIRAPINEXR Product Monograph_
Page 1 of 65
PRODUCT MONOGRAPH
Pr
APO-NEVIRAPINE
NEVIRAPINE TABLETS USP
200 MG
PR
APO-NEVIRAPINE XR
NEVIRAPINE EXTENDED-RELEASE TABLETS
400 MG ANTIRETROVIRAL AGENT
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
WITH ACTIVITY AGAINST
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
SEPTEMBER 11, 2014
TORONTO, ONTARIO
M9L 1T9
CONTROL NO. 177473
_APO-NEVIRAPINE and APO-NEVIRAPINEXR Product Monograph_
Page 2 of 65
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................ 3
SUMMARY PRODUCT INFORMATION
.................................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.......................................................................................................
14
DRUG INTERACTIONS
........................................................................................................
21
DOSAGE AND ADMINISTRATION
.......................................................................................
36
OVERDOSAGE
.....................................................................................................................
37
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
38
STORAGE AND STABILITY
.................................................................................................
40
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................................... 41
PART II: SCIENTIFIC INFORMATION
...........................................................................